Circulating Cell-Free DNA in Renal Cell Carcinoma: The New Era of Precision Medicine
Edoardo Francini, Giuseppe Nicolò Fanelli, Filippo Pederzoli, Sándor Spisák, Erika Minonne, Massimiliano Raffo, Hubert Pakula, Viktória Tisza, Cristian Scatena, Antonio Giuseppe Naccarato, Massimo Loda, Pier Vitale Nuzzo
Abstract
Tumor biopsy is still the gold standard for diagnosing and prognosis renal cell carcinoma (RCC). However, its invasiveness, costs, and inability to accurately picture tumor heterogeneity represent major limitations to this procedure. Analysis of circulating cell-free DNA (cfDNA) is a non-invasive cost-effective technique that has the potential to ease cancer detection and prognosis. In particular, a growing body of evidence suggests that cfDNA could be a complementary tool to identify and prognosticate RCC while providing contemporary mutational profiling of the tumor. Further, recent research highlighted the role of cfDNA methylation profiling as a novel method for cancer detection and tissue-origin identification. This review synthesizes current knowledge on the diagnostic, prognostic, and predictive applications of cfDNA in RCC, with a specific focus on the potential role of cell-free methylated DNA (cfMeDNA).